

Congress revisits 340B without clear path

By [Maya Goldman](#) - Axios

Congress has debated what to do about 340B program growth while still ensuring the program helps providers care for underserved patients. But consensus has been elusive.

Driving the news: A bipartisan group of House lawmakers is pushing for language in a fiscal 2027 spending bill that would block federal funds from being used to create a model in which hospitals in the program pay up front and then get rebates.

- A separate group of House Republicans last fall introduced a drug industry-backed bill that would make changes like additional reporting requirements for providers and new eligibility limits.

The Senate has its own bipartisan 340B working group, and the chamber's health committee held a hearing on the program this fall. But there's been no follow-up.

Reality check: Federal lawmakers have been saying they want to make changes to the program for years, without much meaningful movement.

- States have been far more willing to set guardrails: More than 20 now prevent drugmakers from restricting the pharmacies where providers can use 340B discounts.
- A few states are embracing more pharma-friendly policies. Indiana wants to end Medicaid reimbursement for 340B drugs. Critics say the policy would undermine the health care safety net.